Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 305

1.

The evolution of electrocardiographic signs of right ventricular overload after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.

Piłka M, Darocha S, Banaszkiewicz M, Florczyk M, Wieteska M, Dobosiewicz A, Mańczak M, Mańczak R, Pietrasik A, Pietura R, Torbicki A, Kurzyna M.

Pol Arch Intern Med. 2019 Jun 25. doi: 10.20452/pamw.14877. [Epub ahead of print]

2.

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.

Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.

PMID:
31109190
3.

The multiple systemic artery to pulmonary artery fistulas resulting in severe irreversible pulmonary arterial hypertension in patient with previous history of pneumothorax.

Jacheć W, Tomasik A, Kurzyna M, Pietura R, Torbicki A, Głowacki J, Nowalany-Kozielska E, Wojciechowska C.

BMC Pulm Med. 2019 Apr 16;19(1):80. doi: 10.1186/s12890-019-0832-8.

4.

Proposed new pulmonary hypertension definition: is 4 mm(Hg) worth re-writing medical textbooks?

Gibbs JSR, Torbicki A.

Eur Respir J. 2019 Mar 28;53(3). pii: 1900197. doi: 10.1183/13993003.00197-2019. Print 2019 Mar. No abstract available.

PMID:
30923179
5.

Augmented reality and three-dimensional printing in percutaneous interventions on pulmonary arteries.

Witowski J, Darocha S, Kownacki Ł, Pietrasik A, Pietura R, Banaszkiewicz M, Kamiński J, Biederman A, Torbicki A, Kurzyna M.

Quant Imaging Med Surg. 2019 Jan;9(1):23-29. doi: 10.21037/qims.2018.09.08.

6.

Assessing the severity of acute pulmonary embolism: back to the future?

Torbicki A.

Eur Heart J. 2019 Mar 14;40(11):911-913. doi: 10.1093/eurheartj/ehz018.

PMID:
30726904
7.

Diagnosis of pulmonary hypertension.

Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801904. doi: 10.1183/13993003.01904-2018. Print 2019 Jan.

8.

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.

Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM.

Lancet Respir Med. 2019 Mar;7(3):239-248. doi: 10.1016/S2213-2600(18)30367-9. Epub 2018 Nov 23.

PMID:
30477763
9.

Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D.

Semin Arthritis Rheum. 2019 Jun;48(6):1059-1067. doi: 10.1016/j.semarthrit.2018.10.010. Epub 2018 Oct 14.

PMID:
30415942
10.

Response to letter from dr Altmayer regarding publication "Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics".

Darocha S, Banaszkiewicz M, Pietrasik A, Piłka M, Florczyk M, Wieteska M, Dobosiewicz A, Szmit S, Torbicki A, Kurzyna M.

Int J Cardiol. 2019 Feb 1;276:240-241. doi: 10.1016/j.ijcard.2018.10.103. Epub 2018 Oct 30. No abstract available.

PMID:
30414750
11.

Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy.

Araszkiewicz A, Darocha S, Pietrasik A, Pietura R, Jankiewicz S, Banaszkiewicz M, Sławek-Szmyt S, Biederman A, Mularek-Kubzdela T, Lesiak M, Torbicki A, Kurzyna M.

Int J Cardiol. 2019 Mar 1;278:232-237. doi: 10.1016/j.ijcard.2018.10.066. Epub 2018 Oct 25.

PMID:
30409735
12.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

13.

Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.

Agnelli G, Becattini C, Bauersachs R, Brenner B, Campanini M, Cohen A, Connors JM, Fontanella A, Gussoni G, Huisman MV, Lambert C, Meyer G, Muñoz A, Abreu de Sousa J, Torbicki A, Verso M, Vescovo G; Caravaggio Study Investigators.

Thromb Haemost. 2018 Sep;118(9):1668-1678. doi: 10.1055/s-0038-1668523. Epub 2018 Aug 13.

PMID:
30103252
14.

Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.

Darocha S, Banaszkiewicz M, Pietrasik A, Piłka M, Florczyk M, Wieteska M, Dobosiewicz A, Szmit S, Torbicki A, Kurzyna M.

Int J Cardiol. 2018 Oct 15;269:283-288. doi: 10.1016/j.ijcard.2018.07.015. Epub 2018 Jul 3.

PMID:
30017517
15.

Pregnancy as a predictor of deviations from the recommended diagnostic pathway in women with suspected pulmonary embolism: ZATPOL registry data.

Fijałkowska A, Szczerba E, Szewczyk G, Budaj-Fidecka A, Burakowski J, Sobkowicz B, Nowowiejska-Wiewióra A, Opolski G, Torbicki A, Kurzyna M; Investigators ZATPOL Registry.

Arch Med Sci. 2018 Jun;14(4):838-845. doi: 10.5114/aoms.2017.70896. Epub 2017 Oct 20.

16.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

17.

2018 ESC Guidelines for the diagnosis and management of syncope.

Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martín A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG; ESC Scientific Document Group .

Eur Heart J. 2018 Jun 1;39(21):1883-1948. doi: 10.1093/eurheartj/ehy037. No abstract available.

18.

Practical Instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope.

Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martín A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG; ESC Scientific Document Group .

Eur Heart J. 2018 Jun 1;39(21):e43-e80. doi: 10.1093/eurheartj/ehy071. No abstract available.

PMID:
29562291
19.

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis.

Darocha S, Wilk M, Walaszkowska-Czyż A, Kępski J, Mańczak R, Kurzyna M, Torbicki A, Szmit S.

In Vivo. 2018 Mar-Apr;32(2):373-379.

20.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

Supplemental Content

Loading ...
Support Center